Please use this identifier to cite or link to this item:
Type: Artigo
Title: Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression : a randomized placebo-controlled trial
Author: Palhano-Fontes, Fernanda
Barreto, Dayanna
Onias, Heloisa
Andrade, Katia C.
Novaes, Morgana M.
Pessoa, Jessica A.
Mota-Rolim, Sergio A.
Osorio, Flavia L.
Sanches, Rafael
dos Santos, Rafael G.
Tofoli, Luis Fernando
Silveira, Gabriela de Oliveira
Yonamine, Mauricio
Riba, Jordi
Santos, Francisco R.
Silva-Junior, Antonio A.
Alchieri, Joao C.
Galvao-Coelho, Nicole L.
Lobao-Soares, Bruno
Hallak, Jaime E. C.
Arcoverde, Emerson
Maia-de-Oliveira, Joao P.
Araujo, Draulio B.
Abstract: Recent open-label trials show that psychedelics, such as ayahuasca, hold promise as fast-onset antidepressants in treatment-resistant depression. To test the antidepressant effects of ayahuasca, we conducted a parallel-arm, double-blind randomized placebo-controlled trial in 29 patients with treatment-resistant depression. Patients received a single dose of either ayahuasca or placebo. We assessed changes in depression severity with the Montgomery-angstrom sberg Depression Rating Scale (MADRS) and the Hamilton Depression Rating scale at baseline, and at 1 (D1), 2 (D2), and 7 (D7) days after dosing. We observed significant antidepressant effects of ayahuasca when compared with placebo at all-time points. MADRS scores were significantly lower in the ayahuasca group compared with placebo at D1 and D2 (p = 0.04), and at D7 (p < 0.0001). Between-group effect sizes increased from D1 to D7 (D1: Cohen's d = 0.84; D2: Cohen's d = 0.84; D7: Cohen's d = 1.49). Response rates were high for both groups at D1 and D2, and significantly higher in the ayahuasca group at D7 (64% v. 27%; p = 0.04). Remission rate showed a trend toward significance at D7 (36% v. 7%, p = 0.054). Conclusions To our knowledge, this is the first controlled trial to test a psychedelic substance in treatment-resistant depression. Overall, this study brings new evidence supporting the safety and therapeutic value of ayahuasca, dosed within an appropriate setting, to help treat depression
Subject: Depressão
Country: Reino Unido
Editor: Cambridge University Press
Rights: Fechado
Identifier DOI: 10.1017/S0033291718001356
Date Issue: 2019
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
000458753100014.pdf442.63 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.